.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers recently evaluated zanidatamab gastroesophageal cancer therapy in a groundbreaking Phase 3 trial for HER2-positive patients. This dual HER2-targeted bispecific antibody shows significant promise as a first-line treatment option. Therefore, the study compared zanidatamab, both with and without the anti-PD-1 agent tislelizumab, against the standard-of-care trastuzumab and chemotherapy regimen.
The trial results demonstrate that zanidatamab-based regimens significantly extend progression-free survival. Specifically, patients receiving zanidatamab plus chemotherapy achieved a median progression-free survival of 12.4 months. Similarly, those receiving the triplet combination including tislelizumab also saw a median of 12.4 months. In contrast, the control group receiving trastuzumab and chemotherapy reached only 8.1 months. Consequently, these findings suggest a superior alternative for HER2-positive advanced adenocarcinoma management.
Safety profiles remained manageable across all treatment arms. Although adverse events occurred, they aligned with the known profiles of these specific agents. Furthermore, the overall survival data trended in favor of the zanidatamab groups. As a result, clinicians should consider these results when determining optimal first-line strategies for metastatic gastroesophageal cancer.
Zanidatamab is a bispecific antibody designed to bind two distinct HER2 epitopes. This mechanism enhances HER2 signal blockade and promotes receptor internalization compared to traditional monoclonal antibodies.
In this Phase 3 trial, zanidatamab-based regimens reduced the risk of disease progression or death by approximately 35% to 37% compared to trastuzumab. Both zanidatamab arms showed a median progression-free survival of 12.4 months versus 8.1 months for trastuzumab.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. The information provided should not be used for diagnosing or treating a health problem or disease. Always seek the advice of your physician or another qualified health provider regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Shitara K et al. Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. N Engl J Med. 2026 May 28. doi: 10.1056/NEJMoa2517729. PMID: 42202319.
ClinicalTrials.gov. A Study of Zanidatamab Plus Chemotherapy With or Without Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastroesophageal Adenocarcinoma (HERIZON-GEA-01). Identifier: NCT05152147.
American Society of Clinical Oncology (ASCO). New Frontiers in HER2-Targeted Therapy for Gastrointestinal Malignancies. 2025.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Zanidatamab combinations significantly improve progression-free survival compared to trastuzumab in HER2-positive gastroesophageal adenocarcinoma....
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
